title: Distribution of low-density lipoprotein and high-density lipoprotein subclasses in patients with sarcoidosis.
abstract: BACKGROUND
  Systemic inflammatory diseases are associated with proatherogenic lipoprotein profile, but there is a lack of information regarding overall distributions of lipoprotein subclasses in sarcoidosis.
  
  
  OBJECTIVE
  To investigate whether patients with sarcoidosis have altered distributions of plasma low-density lipoprotein (LDL) and high-density lipoprotein (HDL) particles.
  
  
  METHODS
  Seventy-seven patients with biopsy-proven sarcoidosis (29 with acute and 48 with chronic sarcoidosis) treated with corticosteroids and 77 age- and sex-matched controls were included in the study. Low-density lipoprotein and HDL subclasses were determined by gradient gel electrophoresis, while inflammatory markers and lipid parameters were measured by standard laboratory methods.
  
  
  RESULTS
  Compared to controls, patients had fewer LDL I subclasses (P < .001), but more LDL II and III (P < .001) subclasses. This pattern was evident in both acute and chronic disease groups. Patients also had smaller HDL size (P < .001) and higher proportions of HDL 2a (P = .006) and 3a particles (P = .004). Patients with chronic sarcoidosis had smaller LDL size than those with acute disease (P = .02) and higher proportions of HDL 3a subclasses (P = .04) than controls. In acute sarcoidosis, relative proportions of LDL and HDL particles were associated with levels of inflammatory markers, whereas in chronic disease an association with concentrations of serum lipid parameters was found.
  
  
  CONCLUSIONS
  The obtained results demonstrate adverse lipoprotein subfraction profile in sarcoidosis with sustained alterations during disease course. Evaluation of LDL and HDL particles may be helpful in identifying patients with higher cardiovascular risk, at least for prolonged corticosteroid therapy due to chronic disease course.
authors.affiliation: From the Department of Medical Biochemistry, Faculty of Pharmacy, University of Belgrade, Belgrade, Serbia (Drs Vekic, Zeljkovic, Jelic-Ivanovic, Spasojevic-Kalimanovska, and Spasic and Mses Ivanisevic and Gojkovic); and the Institute for Pulmonary Diseases and Tuberculosis, Clinical Centre of Serbia, Medical Faculty, University of Belgrade, Belgrade, Serbia (Drs Videnovic-Ivanov and Vucinic-Mihailovic).
authors.forename: Jelena
authors.initials: J
authors.lastname: Vekic
authors.forename: Aleksandra
authors.initials: A
authors.lastname: Zeljkovic
authors.forename: Zorana
authors.initials: Z
authors.lastname: Jelic-Ivanovic
authors.forename: Vesna
authors.initials: V
authors.lastname: Spasojevic-Kalimanovska
authors.forename: Slavica
authors.initials: S
authors.lastname: Spasic
authors.forename: Jelica
authors.initials: J
authors.lastname: Videnovic-Ivanov
authors.forename: Jasmina
authors.initials: J
authors.lastname: Ivanisevic
authors.forename: Violeta
authors.initials: V
authors.lastname: Vucinic-Mihailovic
authors.forename: Tamara
authors.initials: T
authors.lastname: Gojkovic
mesh_terms: D000208:Acute Disease; D000305:Adrenal Cortex Hormones / Q000627:therapeutic use; D000328:Adult; D002318:Cardiovascular Diseases; D016022:Case-Control Studies; D002908:Chronic Disease; D005260:Female; D006801:Humans; D008075:Lipoproteins, HDL / Q000097:blood* / Q000145:classification*; D008077:Lipoproteins, LDL / Q000097:blood* / Q000145:classification*; D008297:Male; D008875:Middle Aged; D012044:Regression Analysis; D012307:Risk Factors; D012507:Sarcoidosis / Q000097:blood* / Q000188:drug therapy
chemical_list: D000305:Adrenal Cortex Hormones; D008075:Lipoproteins, HDL; D008077:Lipoproteins, LDL